Together, these findings indicate that IL-1β may act as both a biomarker of inflammation and a functional mediator of tumor behavior, particularly in genetically defined subgroups such as TP53-mutated or PD-L1-high NSCLC. The gene discussed is IL1B; the disease is non-small cell lung carcinoma.